A clinical study comparing oral formulations containing 7.5% calcium sodium phosphosilicate (novamin®), 5% potassium nitrate, and 0.4% stannous fluoride for the management of dentin hypersensitivity

Journal of Clinical Dentistry

Volumn 21, Issue 3, 2010, Pages 88-92

  Sharma, Neeru ^a   Roy, Subrata ^a   Kakar, Ajay ^a   Greenspan, David C ^b   Scott, Randy ^c  

^a Armed Forces Medical Center   (India)

^b Spinode Consulting   (United States)

^c NovaMin Technology Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESENSITIZING AGENT; GLASS; NITRATE; NOVAMIN; POTASSIUM DERIVATIVE; POTASSIUM NITRATE; SILICATE; TIN FLUORIDE; TOOTHPASTE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENTIN SENSITIVITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; NONPARAMETRIC TEST; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANALYSIS OF VARIANCE; DENTIFRICES; DENTIN DESENSITIZING AGENTS; DENTIN SENSITIVITY; DOUBLE-BLIND METHOD; FEMALE; GLASS; HUMANS; MALE; MIDDLE AGED; NITRATES; PAIN MEASUREMENT; POTASSIUM COMPOUNDS; SILICATES; STATISTICS, NONPARAMETRIC; TIN FLUORIDES; YOUNG ADULT;

EID: 78751505042     PISSN: 08958831     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Chabanski MB, Gillam DG. Aetiology, prevalence and clinical features of cervical dentine sensitivity. J Oral Rehabil 1997; 24: 15-19.
2. Dababneh RH, Khouri AT, Addy M. Dentine hypersensitivity- an enigma? A review of terminology, mechanisms, aetiology and management. Br Dent J 1999; 187: 606-611.
3. Liu HC, Lan WH, Hsieh CC. Prevalence and distribution of cervical dentin hypersensitivity in a population in Taipei, Taiwan. J Endod 1998; 24: 45-47.
4. Chabanski MB, Gillam DG, Bulman JS, Newman HN. Clinical evaluation of cervical dentine sensitivity in a population of patients referred to a specialist periodontology department: a pilot study. J Oral Rehabil 1997; 24: 666-672.
5. Gysi A: An attempt to explain the sensitiveness of dentin. Br J Dent Sci 1900; 43: 865-868.
6. Brännström M. The hydrodynamic theory of dentinal pain: sensation in preparations, caries and the dentinal crack syndrome. J Endod 12: 453-457.
7. Brännström M, Linden LA, Aström A. The hydrodynamics of the dental tubule and of pulp fluid. A discussion of its significance in relation to dentinal sensitivity. Caries Res 1967; 1: 310-317.
8. Absi EG, Addy M, Adams D. Dentine hypersensitivity: the development and evaluation of a replica technique to study sensitive and non-sensitive cervical dentine. J Clin Periodontal 1989; 16: 190-195.
9. Markowitz K. The original desensitizers: strontium and potassium salts. J Clin Dent 2009; 20(Spec Iss): 145-151.
10. Orchardson R. Strategies for the management of dentine hypersensitivity. In: Tooth Wear and Sensitivity, Addy M, Embery G, Edgar WM, Orchardson R, eds. Martin Dunitz Ltd, London, pp. 315-325, 2000.
11. Kanapka JA. Over-the-counter dentifrices in the treatment of tooth hypersensitivity: Review of clinical studies. Dent Clin North Am 1990; 34: 545-560.
12. Trowbridge HO, Silver DR. A review of current approaches to in-office management of tooth hypersensitivity. Dent Clin North Am 1990; 34: 561-581.
13. Orchardson R, Gillam DG. The efficacy of potassium salts as agents for treating dentin hypersensitivity. J Orofac Pain 2000; 14: 9-19.
14. Kobler A, Kub O, Schaller HG, Gernhardt CR. Clinical effectiveness of a strontium chloride-containing desensitizing agent over 6 months: A randomized, double-blind, placebo-controlled study. Quintessence Int 2008; 39: 321-325.
15. West NX, Addy M, Jackson RJ, Ridge DB. Dentine hypersensitivity and the placebo response: A comparison of the effect of strontium acetate, potassium nitrate and fluoride toothpastes. J Clin Periodontal 1997; 24: 209-215.
16. Minkoff S, Axelrod S. Efficacy of strontium chloride in dental hypersensitivity. J Periodontal 1987; 58: 470-474.
17. Addy M, Mostafa P, Newcombe R. Dentine hypersensitivity: A comparison of five toothpastes used during a 6-week treatment period. Br Dent J 1987; 163: 45-51.
18. Uchida A, Wakano Y, Fukuyama O, Miki T, Iwayama Y, Okada H. Controlled clinical evaluation of a 10% strontium chloride dentifrice in treatment of dentin hypersensitivity following periodontal surgery. J Periodontal 1980; 51: 578-581.
19. Thrash WJ, Dodds MW, Jones DL. The effect of stannous fluoride on dentinal hypersensitivity. Int Dent J 1994; 44(Suppl 1 ): 107-118.
20. Blong MA, Voiding B, Thrash WJ, Jones DL. Effects of a gel containing 0.4 percent stannous fluoride on dentinal hypersensitivity. Dent Hyg 1985; 59: 489-492.
21. Miller JT, Shannon IL, Kilgore WG, Bookman JE. Use of a water-free stannous fluoride-containing gel in the control of dental hypersensitivity. J Periodontal 1969; 40: 490-491.
22. Schiff T, He T, Sagel L, Baker R. Efficacy and safety of a novel stabilized stannous fluoride and sodium hexametaphosphate dentifrice for dentinal hypersensitivity. J Contemp Dent Pract 2006; 7: 1-8.
23. Schiff T, Saletta L, Baker RA, Winston JL, He T. Desensitizing effect of a stabilized stannous fluoride/sodium hexametaphosphate dentifrice. Compend Contin Educ Dent 2005; 26(Suppl 1): 35-40.
24. Tinanoff N. Progress regarding the use of stannous fluoride in clinical dentistry. J Clin Dent 1995; 6(Spec Iss): 37-40.
25. Greenspan DC. NovaMin® and tooth sensitivity- An overview. J Clin Dent 2010; 21(Spec Iss): 61-65.
26. Jennings DT, McKenzie KM, Greenspan DC, Clark AE. Quantitative analysis of tubule occlusion using NovaMin® (sodium calcium phosphosilicate). J Dent Res 2006; 83(Spec Iss C): 2416.
27. Burwell A, Greenspan DC. Quantitative tubule occlusion in an in vitro remineralization/demineralization model. J Dent Res 2006;85(Spec Iss C): 568.
28. Litkowski LJ, Hack GD, Sheaffer HB, Greenspan DC. Occlusion of dentin tubules by 45S5 Bioglass®. In: Bioceramics 10, Proceedings of the 10th International Symposium on Ceramics in Medicine, Paris, France. Sedel L, Rey C, eds., 1997.
29. United States Department of Health and Human Services Food and Drug Administration. Federal Register 1991; 56: 48308-43810.
30. Wefel JS. NovaMin: likely clinical success. Adv Dent Res 2009; 21: 40-43.
31. LaTorre G, Greenspan DC. The role of ionic release from NovaMin (calcium sodium phosphosilicate) in tubule occlusion: An exploratory in vitro study using radio-labeled isotopes. J Clin Dent 2010; 21(Spec Iss): 72-76.
32. Greenspan DC. NovaMin and tooth sensitivity-An overview. J Clin Dent 2010: 61-65.
33. Curro FA. Tooth hypersensitivity in the spectrum of pain. Dent Clin North Am 1990; 34: 429-437.
34. Curro FA, Friedman M, Leight RS. Design and conduct of clinical trials on dentin hypersensitivity. In: Tooth Wear and Sensitivity, Addy M, Embery G, Edgar MW, Orchardson R, eds. Martin Dunitz Ltd., London, 2000, pp. 299-314.
35. Litkowski L, Greenspan DC. A clinical study of the effect of calcium sodium phosphosilicate on dentin hypersensitivity-Proof of principle. J Clin Dent 2010; 21(Spec Iss): 77-81.
36. Salian S, Thakur S, Kulkarni S. A randomized controlled clinical study evaluating the efficacy of two desensitizing dentifrices. J Clin Dent 2010; 21(Spec Iss): 82-87.
37. Pradeep AR, Sharma A. Comparison of clinical efficacy of a dentifrice containing calcium sodium phosphosilicate to a dentifrice containing potassium nitrate and to a placebo on dentinal hypersensitivity: A randomized clinical trial. J Periodontal 2010; 81: 1167-1173.
38. Du Min Q, Bian Z, Jiang H, Greenspan DC, Burwell AK, Zhong J, Tai BJ. Clinical evaluation of a dentifrice containing calcium sodium phosphosilicate (novamin) for the treatment of dentin hypersensitivity. Am J Dent 2008; 21: 210-214.